Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
Demo Company

Genetic Techniques May Lead to New Therapeutic Approaches for Cardiovascular Diseases

By BiotechDaily International staff writers
Posted on 19 Jun 2014
A review summarized the state-of-the-art in the field of genome-based therapies for cardiovascular diseases.

Despite statistics showing that the death rate from heart disease has fallen about 39% percent over the past 10 years, heart disease remains the number-one cause of death in the United States, killing almost 380,000 people a year. As several recent approaches to treating the wide range of heart diseases have failed for lack of efficacy, the author of the review, Dr. Daniel J. Rader, professor of genetics at the University of Pennsylvania (Philadelphia, USA) has suggested that human genetics-based technologies have the potential to identify new targets for which the likelihood of therapeutic success is considerably greater.

Among the problems he cited in the June 4, 2014, issue of the journal Science Translational Medicine were (1) many biopharmaceutical companies have begun to back away from efforts to discover and develop therapies for this prevalent disease; (2) seven drugs have failed in phase III clinical trials in the last three to five years; and (3) animal models of atherosclerosis have not proven reliable at predicting new therapies that are effective in humans.

Dr. Rader suggested that as with recent successes in cancer immunotherapy, basing drug targets on human genetics may provide greater confidence that a therapeutic targeted to a particular pathway will show clinical benefit in reducing major cardiovascular events in people. In the review he cited studies of common variants associated with cardiovascular diseases that had yielded nearly 50 statistically significantly associated discrete genetic loci genome-wide. Less than a third were associated with such traditional risk factors as LDL-C (low density lipoprotein-cholesterol) levels or blood pressure, leaving more than 30 loci with no association with traditional measureable risk factors.

"Some of the most interesting new targets for atherosclerotic cardiovascular disease are likely to come from genetic studies of common and rare variants, comparing individuals with early disease with those who are free of disease," said Dr. Rader.

Related Links:
University of Pennsylvania



Channels

Lab Technologies

view channel
Image: The ChilliBlock modular system for precise, controlled cooling and heatingof biological samples (Photo courtesy of Asynt).

Modular Cooling/Heating System Safeguards Temperature-Sensitive Biological Samples

A new modular system designed for precise, controlled cooling and heating of biological samples in microplates, vials and Eppendorf tubes is now available for biotech, clinical, and life science laboratories.... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.